Prostaglandin derivatives
AssigneesResearch Development Corporation, Masami Tsuboshima
InventorsShuh Narumiya, Osamu Hayaishi, Yoshiharu Kimura, Masami Tsuboshima
Life of this patent
Estimating the term…
Abstract
Permeability characterized in that the carboxy group at 1-position of the prostaglandin is combined with a cell membrane permeable substance having hydroxy group or amino group through the intermediation of an ester bond to the hydroxy group or an amide bond to the amino group are novel and have improved cell membrane permeability.
Claims5
A compound selected from the group consisting of (a) an ester of a prostaglandin with an alcohol selected from the group consisting of retinol and hydroxyacetylretinol, and (b) prostaglandin phenothiazine amide;
- the prostaglandin of the prostaglandin ester and the prostaglandin of the prostaglandin phenothiazine amide, each being selected from the group consisting of PGA.sub.1, PGA.sub.2, PGB.sub.1, PGB.sub.2, PGC.sub.2, PGD.sub.2, PGE.sub.1, PGE.sub.2, PGE.sub.3, PGF.sub.1.alpha., PGF.sub.2.alpha., PGF.sub.3.alpha., PGG.sub.2, PGH.sub.2, PGI.sub.2, .DELTA..sup.12 -PGJ.sub.2, 9,11 -dimethylmethano-11,12-methano-16-phenyl-13,14-dihydro-13-aza-15.alpha..be ta.-.omega.-tetranorthromboxan-A.sub.2 (ONO-1120), and 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl-hydantoin(BW245C).
A method of treating a subject with a disease ameliorated by hypotensive activity, diuretic activity, metabolic activity, bronchiectasic activity, uterotonic activity, thyrotropic activity, neuro stimulating activity, gastric juice secretion inhibiting activity, fatty acid release inhibiting activity and carcinostatic activity, said method comprising administering an effective dose of an ester of a prostaglandin with an alcohol selected from the group consisting of retinol, hydroxyacetylretinol and anthracene-9-methanol or prostaglandin phenothiazine amide;
- the prostaglandin of the prostaglandin ester and the prostaglandin of the prostaglandin phenothiazine amide, each being selected from the group consisting of PGA.sub.1, PGA.sub.2, PGB.sub.1, PGB.sub.2, PGC.sub.2, PGD.sub.2, PGE.sub.1, PGE.sub.2, PGE.sub.3, PGF.sub.1.alpha., PGF.sub.2.alpha., PGF.sub.3.alpha., PGG.sub.2, PGH.sub.2, PGI.sub.2, .DELTA..sup.12 -PGJ.sub.2, 9,11-dimethylmethano-11,12-methano-16-phenyl-13,14-dihydro-13-aza-15.alpha ..beta.-.omega.-tetranor-thromboxan-A.sub.2 (ONO-1120), and 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl-hydantoin(BW245C).
A method of providing enhanced permeation of a prostaglandin into cells, said method comprising introducing into said cells ester of said prostaglandin with an alcohol being selected from the group consisting of retinol, hydroxyacetylretinol and anthracene-9-methanol or phenothiazine amide of said prostaglandin;
- said prostaglandin being selected from the group consisting of PGA.sub.1, PGA.sub.2, PGB.sub.1, PGB.sub.2, PGC.sub.2, PGD.sub.2, PGE.sub.1, PGE.sub.2, PGE.sub.3, PGF.sub.1.alpha., PGF.sub.2.alpha., PGF.sub.3.alpha., PGG.sub.2, PGH.sub.2, PGI.sub.2, .DELTA..sup.12 -PGJ.sub.2, 9,11-dimethylmethano-11,12-methano-16-phenyl-13,14-dihydro-13-aza-15.alpha ..beta.-.omega.-tetranor-thromboxan-A.sub.2 (ONO-1120), and 5-(6-carboxyhexyl)-1-(3-cyclohexyl-3-hydroxypropyl-hydantoin(BW245C).
Dependencies are inferred from the claim text.